Beam Therapeutics Inc. is a clinical-stage biotechnology company that develops precision genetic medicines using its proprietary base editing technology. Headquartered in Cambridge, Massachusetts, the company focuses on creating therapies that make precise, single-base changes in DNA without causing double-strand breaks. Its pipeline targets serious diseases across hematology, oncology, immunology, and genetic conditions, with key programs including treatments for sickle cell disease and alpha-1 antitrypsin deficiency (AATD). Beam operates primarily through research collaborations, strategic partnerships, and licensing agreements to advance its preclinical and clinical candidates. The company's distinctive approach to gene editing aims to correct disease-causing mutations at their source.
